Sero-prevalence of cryptococcal antigen and its immune-virological correlates in HIV-1 positive individuals: a prospective cross-sectional study

HIV-1阳性个体中隐球菌抗原血清阳性率及其免疫病毒学相关性:一项前瞻性横断面研究

阅读:2

Abstract

BACKGROUND: Cryptococcal infection remains a leading cause of mortality among HIV-1-positive individuals, particularly in regions with limited access to antiretroviral therapy and diagnostics. This study aimed to assess Cryptococcal Antigen (CrAg) seroprevalence and its immune-virological correlates among ART-naïve and ART-experienced HIV-1 positive individuals. METHODS: This prospective cross-sectional study was conducted from May 2023 to August 2024 at Edo State University Teaching Hospital, Nigeria. Blood samples were analyzed for CD4 + T-cell counts using a Partec™ CyFlow analyzer, HIV-1 viral load using the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) Test, and CrAg detection with the Immy Latex-Crypto Antigen Lateral Flow Assay. RESULTS: Among 229 HIV-1 positive individuals, 72.5% were aged 15-20 years, and 69% were female. Most (68.6%) were ART-experienced, while 31.4% were ART-naïve. Severe immunosuppression (CD4 + < 200 cells/mm³) was present in 64.6%, and 71.2% had viral loads > 1,000 copies/mL. Cryptococcal infection (CI) prevalence was 10.04%. No significant link was found between CI and age or gender, but ART-naïve status, low CD4 + counts, and high viral loads were significantly associated with CI. ART-naïve individuals had higher viral loads (median 4.95 vs. 4.19 log10 copies/mL, p = 0.00). A stronger inverse correlation between CD4 + counts and viral load was observed in ART-experienced patients (r = -0.535). CONCLUSIONS: These findings emphasize the necessity for routine Cryptococcal screening, particularly in ART-naïve and severely immunocompromised individuals, to facilitate timely interventions and improve clinical outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。